Key result
Routine long-term beta-blocker therapy may not provide a survival benefit after myocardial infarction in patients without heart failure or left ventricular dysfunction receiving contemporary treatments.
Why the study?
Does beta-blocker therapy reduce mortality in patients after a myocardial infarction without heart failure or left ventricular dysfunction?
Does beta-blocker therapy reduce mortality in patients after a myocardial infarction without heart failure or left ventricular dysfunction?
The paper highlights clinical uncertainty regarding the routine use of beta-blockers post-MI in patients without heart failure, calling for new randomized trials to reevaluate this practice.
Does not support routine long-term beta-blockers post-MI without HF or LV dysfunction; leaves open need for contemporary RCTs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Roberto F.E. Pedretti (2018) conducted a review in Myocardial infarction without heart failure or left ventricular dysfunction. Beta-blockers vs. No beta-blockers was evaluated. Routine long-term beta-blocker therapy may not provide a survival benefit after myocardial infarction in patients without heart failure or left ventricular dysfunction receiving contemporary treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: